NCT01004809已完成不适用
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and Effectiveness of AVODART® Administered in Korean Androgenetic Alopecia Patients According to the Prescribing Information
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 712
- 试验地点
- 1
- 主要终点
- Occurrence of adverse event after dutasteride administration
研究概览
简要总结
Post-marketing surveillance(PMS) to monitor the safety and effectiveness of dutasteride in Korean androgenetic alopecia patients
详细描述
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and effectiveness of dutasteride administered in Korean androgenetic alopecia patients according to the prescribing information
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 41 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Men (18-41 years of age) with male pattern hair loss (androgenetic alopecia)
- •Subjects with no experience of treatment using dutasteride
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol
- •Subjects who prescribed with dutasteride according to the Prescribing Information
排除标准
- •Considering the nature of observational study, GSK Korea encourages the doctors participating in this study to enrol the subjects prescribed with dutasteride following the locally approved Prescribing Information. Subject who give informed consent is enrolled. However, if institution waives the requirement for informed consent, informed consent is not required. In this case, monitoring does not proceed.
研究组 & 干预措施
Dutasteride
Patients administrated dutasteride with male hair loss
干预措施: Dutasteride (Drug)
结局指标
主要结局
Occurrence of adverse event after dutasteride administration
时间窗: 2 years
次要结局
- Occurrence of unexpected adverse drug reaction after dutasteride administration(2 years)
- Effectiveness of dutasteride judged by a physician(2 years)
- Occurrence of serious adverse events after dutasteride administration(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast CancerBreast CancerNCT01047358Pfizer206
已完成
不适用
Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid CardiomyopathyATTR-CM (Transthyretin Amyloid Cardiomyopathy)NCT04801329Pfizer110
已完成
不适用
Korean Regulatory Post Marketing Surveillance for SomavertAcromegalyNCT05131100Pfizer11
已完成
不适用
Tiotropium 18ug Inhalation Capsule Using a Handihaler® Among Korean COPD PatientsPulmonary Disease, Chronic ObstructiveNCT00620516Boehringer Ingelheim3,008
已完成
不适用
Regulatory AVAMYS Nasal Spray PMSRhinitis, Allergic, Perennial and SeasonalNCT01001130GlaxoSmithKline3,244